Leveraging Science for Lifetime Medicine

From a one-man discovery to a passionate global drug development team working on the next generation of metabolic and inflammatory therapeutics

From Bench to Bedside

We leverage science to deliver effective, safe, and tolerable lifetime medicine for inflammatory diseases based on our deep understanding of drug research and development, breakthrough mechanisms of action, and global collaborations.

Pipeline
ARMOR Phase 3 Study
Nov. 16, 2026

Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol

Read More
Nov. 10, 2026

Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device

Read More
Sep. 9, 2026

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Read More